Navigation Links
New Blood Test Advances Individualized Cancer Therapy and Cuts Down on Need for Painful Biopsies

Bethesda, MD (PRWEB) July 24, 2014

The first-ever successful isolation and culture of rare tumor cells circulating in a patient’s blood has been achieved by NFCR-supported scientist Daniel Haber, M.D., Ph.D., and his team at Massachusetts General Hospital. This is an important milestone on the road to individualized cancer therapy, a new approach to selecting the best treatment for each patient.

“Tumors evolve in response to treatment,” said Dr. Haber. “They often acquire new genetic features that make them resistant to drugs. If we can monitor those changes in real time, we stand a better chance of matching the right treatments with the right patients against those new changes in their tumors.” With the success of the CTC-iChip, it is now possible to do just that.

The CTC-iChip is a business card-sized device developed by MGH bioengineer Dr. Mehmet Toner, Dr. Haber and their collaborators that can capture extraordinarily rare “circulating tumor cells” (CTCs) from a patient’s blood sample – one tumor cell per billion blood cells. Recent improvements in the chip make it easier to remove CTCs from the filter device and grow them in cell culture dishes in the labs.

As part of the experiment, the researchers took multiple blood samples from women with breast cancer over the course of their treatment, and were able to monitor the development of new mutations in their CTCs. Because this approach starts with a simple blood test, changes in the tumor cells can be assessed over time without the need for repeated, invasive, and painful biopsies.

Using the CTC-derived tumor models grown in the lab, Dr. Haber’s team could also test various combinations of drugs to see which were effective. This technique could provide a new way to help physicians develop personalized cancer treatment plans for individual patients. Dr. Haber and his team are now focused on optimizing CTC culture conditions, improving efficiency, bringing down costs, and meeting the remaining challenges to bring individualized therapy into the clinic.

“At NFCR we take the long view of cancer research, and our support of Dr. Haber’s research over the past decade is paying off,” said Franklin Salisbury, Jr., President of NFCR. “We could not be more proud of what Dr. Haber and his colleagues at MGH have accomplished, and we have every confidence that they will continue to improve this technique, making individualized therapy a reality for cancer patients everywhere.”

Dr. Haber has received NFCR support since 2003. Dr. Haber’s findings were published in the July 11 issue of the journal Science.

About the National Foundation for Cancer Research

The National Foundation for Cancer Research (NFCR) is a leading cancer research charity dedicated to funding cancer research and public education relating to cancer prevention, earlier diagnosis, better treatments and, ultimately, a cure for cancer. NFCR promotes and facilitates collaboration among scientists to accelerate the pace of discovery from bench to bedside. NFCR is committed to Research for a Cure - cures for all types of cancer. For more information, visit or call (800) 321-CURE (2873).

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Infection Might Raise Blood Clot Risk for Older Adults: Study
2. Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines
3. Common Blood Pressure Drug Safe for Heart Failure: Study
4. Certain Birth Control Pills May Carry Higher Blood Clot Risk: FDA
5. High Blood Pressure May Be Especially Lethal for Blacks
6. Changes in gene expression may help explain high blood pressure in pregnancy
7. Researchers Develop Blood Test for Depression
8. Naturopathic care can improve blood sugar, mood in diabetes
9. Diabetes Groups Issue New Guidelines on Blood Sugar
10. Exercise May Help Patients With High Blood Pressure Live Longer
11. Additional blood pressure screening may reduce incidence of CVD events and death by up to 3 percent
Post Your Comments:
(Date:11/25/2015)... ... November 26, 2015 , ... ... (AUC), European Union (EU), ANDI Pan African Centres of Excellence, and public R&D ... Nairobi (UNON) for the opening of the 5th African Network for Drugs and ...
(Date:11/25/2015)... TX (PRWEB) , ... November 25, 2015 , ... For ... the companies’ “ Two Organizations, One Beat ” campaign. The partnership between the two ... services to aid in MAP International’s cause. , MAP International was founded in 1954 ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... encouraging people across the country to celebrate their sobriety and show through pictures ... post “before and after” photos this Thanksgiving with the hashtag #FacesOfGratitude on their ...
(Date:11/25/2015)... ... , ... On November 25, 2015, officials of Narconon Arrowhead , the ... of a new cutting edge recovery program that has been 50 years in the ... alcohol-addicted individuals with the purpose to free addicts from the symptoms and negative behaviors ...
(Date:11/25/2015)... Crystal Lake, IL (PRWEB) , ... November 25, 2015 , ... ... pleased to announce a recent successful appellate decision obtained by Attorneys Francisco J. Botto ... the case Adcock v. Illinois Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... Global Cell Surface Testing Market: Supplier ... to their offering.  --> ... of the  "2016 Future Horizons and ...
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Monitoring (TDM) Market: Supplier Shares, Country ...  report to their offering.  --> ... addition of the  "2016 Future Horizons ...
(Date:11/26/2015)... November 26, 2015 ... the "Radioimmunoassay Market by Type (Reagents ... Industry, Academics, Clinical Diagnostic Labs), Application (Research, ... to 2020" report to their offering. ... the addition of the "Radioimmunoassay Market ...
Breaking Medicine Technology: